About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 13th, 2017

The QualityStocks
Daily Stock List


Organigram Holdings, Inc. (OGRMF)

Cannabis Financial Network News, CFN Media Group, InvestorPlace, Wealth Daily, and Money Morning reported previously on Organigram Holdings, Inc. (OGRMF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Organigram Holdings, Inc.’s emphasis is on producing the highest quality, condition specific medical marijuana for patients in Canada. The Company’s wholly-owned subsidiary, Organigram, Inc., is a licensed producer of medical marijuana in Canada. The Company's head office, production facility, and Research and Development (R&D) are in Moncton, New Brunswick. Organigram Holdings’ shares trade on the OTC Markets Group’s OTCQB.

Organigram Holdings is regulated by the Access to Cannabis for Medical Purposes Regulations (ACMPR). All of the Company’s products are manufactured under strict controls and in conformance with the Good Production Practices of the MMPR, and the security directives as defined by the Office of Controlled Substances. All products are lab tested before packaging and sale.

Organigram provides a varied array of genetics and product types. These cater to the individual needs of each and every client. Organigram offers a reliable supply of premier quality, industry-leading strains to match individuals’ personal needs.

Organigram has collaborations with healthcare experts and academic institutions. The Company invests in medical education, outreach, and research for the use of cannabinoids as a first line of treatment.

Organigram Holdings is undergoing a production-facility expansion. This expansion will more than triple the size of the Company’s operations. The multi-million-dollar project will meet the increasing needs of its medical patient base, and also prepare Organigram for the legal, adult-recreational marijuana market.

The highlights of the Company’s plans include the addition of about 140 new employees by the end of 2018; and an expansion of its existing production facility from 36,000 to 134,000 square feet by the end of 2017, grown on three levels.

Plans also include a further 36,000 square-foot expansion scheduled for completion by mid 2018; a production-capacity increase from roughly 5,200 kilograms (kg) per year to over 25,000 kg per year; and the acquisition of a third building at 55 English Drive for future expansion, next to the current campus.

Recently, Organigram announced that it started the process for re-certification as an organic producer of cannabis in Canada with ECOCERT Canada. As part of the process, Organigram submitted a comprehensive action plan to ECOCERT Canada, outlining its approach to the growing and segregation of both product lines. The design of the plan is to ensure the integrity of organic products within its facility, and was approved by ECOCERT Canada in September of this year. ECOCERT Canada is part of the Ecocert group, one of the largest organic certification organizations in the world.

Organigram Holdings, Inc. (OGRMF), closed Monday's trading session at $2.919, up 14.07%, on 773,015 volume with 1,338 trades. The average volume for the last 60 days is 138,808 and the stock's 52-week low/high is $1.35/$3.3455.

Q BioMed, Inc. (QBIO)

StockPicksNYC, Stock News Now, and SeeThruEquityResearch reported on Q BioMed, Inc. (QBIO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a biomedical acceleration and development company based in New York City. The Company’s commitment is on licensing and acquiring biomedical assets across the healthcare spectrum. The Company formerly went by the name ISMO Tech Solutions, Inc. It changed its name to Q BioMed, Inc. in July of 2015. Q BioMed’s shares trade on the OTC Markets’ OTCQB.

Q BioMed’s dedication is to provide these target assets the strategic resources, developmental support, as well as expansion capital they require to ensure they meet their developmental potential, enabling them to provide products to patients in need. The Company’s corporate mission is to license and acquire pioneering life sciences assets from academia or small private companies.

The Company is concentrating on clinical stage and innovative products where the technical, regulatory, and commercial risks have been lessened or major valuation inflections are pending. It has numerous assets across a broad assortment of healthcare related products, companies, and sectors. These assets will undergo development to provide returns via organic growth or out-licensing, sale, or be spun out into new public companies.

Q BioMed is also developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of IOP (Intraocular Pressure) - one of the main causes of glaucoma. The platform is innovative and first-in-class. Q BioMed, together with its partner, Mannin Research, Inc., is the only company targeting this mechanism of action.

Q BioMed has commenced production of Strontium-89 Chloride. This is a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be utilized in combination with, or to decrease the need for opiate based drugs, as well as in combination with cancer therapeutic drugs.

Q BioMed has entered into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). With the agreement, the Company has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.

In September, Q BioMed announced a partnership with Sphaera Pharma. This is to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. Sphaera Pharma will utilize its proprietary and patented platform to produce a novel analog, which aims to lessen or eliminate potential side effects and can decrease the amount of product a toddler needs to take on a daily basis.

Last month, Q BioMed announced the launch of www.PainFreeCancer.com. The design of this website is to provide a resource for patients, doctors, and caregivers dealing with the severe pain associated with late stage cancer metastases to the bone.

Q BioMed, Inc. (QBIO), closed Monday's trading session at $3.70, up 4.23%, on 85,294 volume with 159 trades. The average volume for the last 60 days is 48,298 and the stock's 52-week low/high is $2.95/$12.61.

Aphria, Inc. (APHQF)

Cannabis Financial Network News and CFN Media Group reported previously on Aphria, Inc. (APHQF), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Aphria, Inc. is one of Canada's lowest cost producers that produces, supplies, and sells medical cannabis. The Company’s medical cannabis products are 100 percent greenhouse grown. Aphria works to provide pharmaceutical-grade medical cannabis and leading patient care. Its commitment is to do this while balancing patient economics and returns to shareholders. Listed on the OTC Markets’ OTCQB, Aphria is based in Leamington, Ontario.

Aphria’s dedication is to ensuring patients receive consistent, safe, and effective medical cannabis products. The Company is a Health Canada Licensed Producer of medical cannabis products. The only legal access to medical cannabis in Canada is through Health Canada Licensed Producers. Nevertheless, some Canadians still have personal production licenses. This grants them authorization to produce medical cannabis for personal use.

The Company’s cannabis oil products are produced using C02 extraction methods. These methods preserve purity and ensure safety. Aphria’s equivalency factor of cannabis oil to dried cannabis is 6:1. Consequently, every 6 mL of cannabis oil is equivalent to 1 gram of dried cannabis.

Aphria is in the middle of a multi-phase expansion program. Upon completion of Part II, the Company expects that yearly production capacity will reach 5,500 kilograms of dried cannabis and 9,000 liters of cannabis oil.

In April 2017, Tetra Bio-Pharma, Inc. (GRPOF) and Aphria announced plans for the joint distribution of dried medical cannabis in the Maritime Provinces and Quebec. Tetra Bio-Pharma and Aphria will enter into a joint supply agreement. Aphria will supply dried medical cannabis under its ACMPR license. Tetra Bio-Pharma will package the product utilizing the manufacturing process developed for its in-progress clinical drug trial for PPP001.

In August 2107, Aphria announced that it invested $11.5 million in HydRx Farms, Ltd. (o/a Scientus Pharma) through a senior, secured convertible debenture. The Debenture has a two-year term, bears interest at the rate of 8 percent, paid semi-annually, and is convertible into the common shares of Scientus Pharma at the rate of $2.75 a share. In addition, it is secured by a first charge on all of the present and future assets of Scientus Pharma.

Scientus Pharma is a vertically-integrated biopharmaceutical company. It concentrates on the development of drugs, which target the endocannabinoid receptors throughout the body for the treatment of diseases of the brain, organs, connective tissues, and more. Scientus Pharma is one of a limited number of Licensed Dealers in Canada authorized to handle and conduct cannabinoid product.

Last month, Aphria announced that it completed its first shipment of cannabis oil to Australian medical life science company, Medlab Clinical Limited. This shipment is part of the earlier announced agreement between Aphria and Medlab Clinical. As such, Aphria will produce and supply high-yield cannabis extracts for Medlab Clinical to be used in its approaching human trial to test management of intractable pain in oncology patients – the first trial of its kind worldwide.

The product formulation and permits have been approved by Health Canada and the Australian Therapeutic Goods Administration (TGA). Aphria will grow and prepare the high-yield cannabis for Medlab Clinical in Canada. Medlab will complete the manufacturing at a licensed Schedule 8 (S8) TGA approved facility, in Melbourne, Australia.

Aphria, Inc. (APHQF), closed Monday's trading session at $7.19, up 6.69%, on 975,634 volume with 2,897 trades. The average volume for the last 60 days is 972 and the stock's 52-week low/high is $3.00/$6.97.

Kush Bottles, Inc. (KSHB)

CFN Media Group, Stock News Now, The Street, StreetAuthority Daily, Promotion Stock Secrets, and SmallCapVoice reported earlier on Kush Bottles, Inc. (KSHB), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Kush Bottles, Inc. is a sales and distribution platform. It offers packaging, supplies, vaporizers, accessories, and branding solutions for the regulated cannabis industry. The Company provides certified child-resistant and custom-branded solutions in all States that allow medical or recreational cannabis use. The Company is the only marijuana packaging company with manifold full-service facilities throughout the U.S. Kush Bottles has its headquarters and California fulfillment center in Santa Ana, California.

The Company now regularly services over 4,000 legally operated medical and adult-use dispensaries, growers, and producers throughout North America, South America, and Europe. Moreover, Kush Bottles has opened a new Product Development and Genomics Lab to produce inventive terpene formulations. The lab is in San Diego, California.

Kush Bottles provides pop top bottles; child resistant exit, paper exit, and foil barrier bags; tubes; and polystyrene, polypropylene, or silicone containers to urban farmers, greenhouse growers, and medical and recreational cannabis dispensaries. Kush focuses on providing the highest quality medical and food grade packaging.

The Company also focuses on selecting products, which are environmentally friendly and manufactured within the U.S. Kush has an in-house marketing and branding team to serve customers. Its team can help a business get their brand off the ground through creating logos, brochures, websites, and custom packaging.

Kush Bottles has launched the marijuana industry's first online system. The system enables customers to design custom-branded packaging solutions. The tool makes it easier for customers to place orders. The expectation is that this will lead to a higher conversion rate and a better Return on Investment (ROI).

Kush Bottles has launched its "Kush N Slide" child resistant exit bag. The Kush N Slide is certified child resistant per Title 16 CFR 1700. The design of it is to meet the strict packaging regulations that are in place in Colorado and Oregon.

Kush Bottles announced earlier in 2017 that it acquired CMP Wellness, LLC (Los Angeles, California). CMP is a privately held distributor of vaporizers, cartridges, and accessories. In addition Kush Bottles announced this year that it acquired the web domain Roll-uh-Bowl.com. This is an online distribution platform for retail sales of collapsible and unbreakable medical-grade silicone water pipes.

This past September, Kush Bottles announced it launched a Food and Drug Administration (FDA) compliant Kush Canister™ to safely and securely store cannabis products for resale purposes. The canister can fit just over one ounce of cannabis flower. The canister has a certified child resistant push-top to comply with regulations in the States that require child resistant packaging.

Manufactured in the United States, the specific design of the proprietary product is for markets that require child resistant packaging. The material used to manufacture this container is food grade and BPA free.

Kush Bottles has created a new professional services program to develop innovative, custom-formed child-resistant packaging systems. It can provide an entire range of packaging solutions. This is from certified child-resistant pop-tops and exit bags, to proprietary and exclusive shapes that create a one-of-a-kind look and feel.

Kush Bottles, Inc. (KSHB), closed Monday's trading session at $2.24, up 0.90%, on 273,138 volume with 368 trades. The average volume for the last 60 days is 102,073 and the stock's 52-week low/high is $1.61/$3.56.

MassRoots, Inc. (MSRT)

SmallCapVoice, Penny Stock 101, Money Morning, Stock News Now, OTCtipReporter, StockRockandRoll, SeeThruEquity Research, Damn Good Penny Picks, Penny Picks, CFN Media Group, Wealth Daily, Cannabis Financial Network News, Equities, The Street, Promotion Stock Secrets, PennyStockLocks, PennyStockScholar, Profitable Trader Authority, Stock Commander, and OTCJournal reported on MassRoots, Inc. (MSRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MassRoots, Inc. is a leading technology platform for medical cannabis patients and businesses. Individuals use its application to share their cannabis experiences and stay connected with local dispensaries. MassRoots has affiliations with the foremost organizations in the cannabis industry. These include the ArcView Group and the National Cannabis Industry Association. MassRoots has its corporate office in Denver, Colorado.

Businesses can use MassRoots to advertise their goods and services to cannabis consumers. MassRoots starts adding in features. These include order ahead, delivery, and the in-app purchase of ancillary products as regulations permit. Cannabis enthusiasts collectively engage greater than 300,000 times per day on MassRoots’ network. The Company’s plan is to expand to numerous states.

MassRoots has some estimated 300-plus dispensaries actively posting on its network. These include the nation's top dispensaries: Native Roots, MiNDFUL, The Clinic, BuddyBoyBrands, Green Solution, Good Chemistry, Denver Relief, Natural Remedies, and Harborside Health Center.

MassRoots’ product pipeline includes Dispensary Finder & Menus; Product Pages & Reviews; Sponsored Posts 2.0; and Enhanced Profiles. The majority of the Company’s advertising revenue has come from dispensaries and cannabis-brands in the States of California and Colorado.

MassRoots completed its acquisition of DDDigtal, d.b.a. "Whaxy" in January 2017. This is an online order-ahead and menu management platform. This past June, MassRoots and HIGH TIMES announced that MassRoots made a strategic investment in High Times Holding Corporation, "High Times", the leading voice of the Cannabis Industry, in February 2017.

HIGH TIMES is the world's leading cannabis media, events, and information business. As disclosed in MassRoots' Quarterly Report on Form 10-Q filed on May 22, 2017, MassRoots made the strategic equity investment in High Times Holdings Corporation.

This past July, MassRoots announced it closed the acquisition of Odava, Inc. for cash and common stock consideration. MassRoots now offers dispensaries a total set of software to manage their regulatory compliance, streamline their supply chain, and develop successful consumer loyalty programs. Odava is a foremost compliance and point-of-sale (POS) system for the cannabis industry.

Subsequently, in August, MassRoots announced the acquisition of CannaRegs, Inc. MassRoots entered into a definitive agreement to acquire CannaRegs in a stock deal valued at roughly $12 million. CannaRegs is a leading technology platform. It tracks changes in cannabis regulations and taxation at the municipal, state, as well as federal levels.

Recently, MassRoots announced the release of its new Dispensary Finder service with 6,000 entries that catalogue all medical, recreational, and delivery-based dispensaries in nine States. The Company launched its Dispensary Finder service together with Sweet Leaf, a top medical and recreational dispensary chain with more than 20 locations in Colorado, California, and Oregon with headquarters in Denver, Colorado, as Dispensary Finder's first promoted customer.

The 6,000 entries available at launch include all dispensaries in Washington, Oregon, California, Arizona, Colorado, Wisconsin, Michigan, New Hampshire and Massachusetts. The expectation is that more States will come on board by the end of 2017.

MassRoots, Inc. (MSRT), closed Monday's trading session at $0.1355, down 21.45%, on 5,712,955 volume with 872 trades. The average volume for the last 60 days is 806,034 and the stock's 52-week low/high is $0.1629/$1.18.

Northwest Biotherapeutics, Inc. (NWBO)

PureActionStocks, Pennybuster, WealthMakers, Wealthpire, CoolPennyStocks, StreetInsider, StockPicksNYC, Streetwise Reports, OTCPicks, FeedBlitz, AllPennyStocks, The Street, Marketbeat, Promotion Stock Secrets, RedChip, Wall Street Corner, BUYINS.NET, INO Market Report, InvestorPlace, BullRally, and SmallCapVoice reported previously on Northwest Biotherapeutics, Inc. (NWBO), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Northwest Biotherapeutics, Inc. is a biotechnology enterprise developing DCVax® personalized immune therapies for solid tumor cancers. In the United States and Europe, the Company’s concentration is on developing personalized immunotherapy products, on a cost-effective basis, designed to treat cancers more effectively than existing treatments. This is without toxicities of the type associated with chemotherapies. Northwest Biotherapeutics has its corporate office in Bethesda, Maryland. The Company lists on the OTCQB.

Northwest Biotherapeutics’ lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). This trial has completed its enrolment.

Northwest Biotherapeutics has a wide-ranging platform technology for DCVax dendritic cell-based vaccines. It is working to move forward with numerous clinical programs, involving DCVax-L and DCVax-Direct.

The Company is pursuing completion of the current Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer and pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs. This includes the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer that was earlier announced.

Northwest Biotherapeutics also previously received clearance from the Food and Drug Administration (FDA) for a 612-patient Phase III trial in prostate cancer. The Company received approval in Germany of a five-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.

In addition, Northwest Biotherapeutics is pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial. It is preparing the Phase II portion. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer in association with the University of Pennsylvania.

In September, Northwest Biotherapeutics announced that Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer (CTO) of the Company presented an update on the Phase III Trial of DCVax®-L for newly diagnosed GBM and the DCVax®-Direct Trials at the Cambridge Healthtech Institute's Immuno-Oncology Summit in Boston, Massachusetts on August 31, 2017.

Dr. Bosch's presentation reflected the scope and consistency of the Company’s DCVax platform and clinical programs, including the 50 patient Information Arm of the DCVax-L trial that included multi-year survival and a long tail; and 40 patient Phase I/II Trials of DCVax-L that included multi-year survival and long tails.

The presentation also included the 41 patient DCVax-Direct Phase I trial for 13 different solid tumor cancers that included multi-year survival and long tails; and a 331 patient Phase III GBM Trial, which the Company said appears, based on the trial metrics reported in the Company's industry presentation during ASCO, may include multi-year survival and a long tail.

Furthermore, the presentation included preclinical studies of DCVax-L combined with checkpoint inhibitor by collaborators that included substantially expanded response rates.

Northwest Biotherapeutics, Inc. (NWBO), closed Monday's trading session at $0.165, up 0.61%, on 1,866,945 volume with 172 trades. The average volume for the last 60 days is 1,558,243 and the stock's 52-week low/high is $0.14/$0.50.

SolarWindow Technologies, Inc. (WNDW)

TopPennyStockMovers, Stock Oodles, Winston Small Cap, Stock Gumshoe, AllPennyStocks, and SmallCapVoice reported earlier on SolarWindow Technologies, Inc. (WNDW), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

SolarWindow Technologies, Inc. is a developer of next generation, transparent, electricity-generating SolarWindow™ coatings. The Company is a developer of electricity-generating windows for tall towers and skyscrapers. The Company formerly went by the name New Energy Technologies, Inc. It changed its corporate name to SolarWindow Technologies, Inc. in March 2015. OTCQB-listed, SolarWindow Technologies is based in Columbia, Maryland.

The Company’s mission has been to create SolarWindow™ products that produce considerable amounts of clean electricity, financially reward its customers, and benefit the environment. SolarWindow Technologies creates transparent electricity-generating liquid coatings. Upon application to glass or plastics, the coatings convert passive windows and other materials into electricity generators under natural, artificial, low, shaded, and reflected light conditions.

SolarWindow™ utilizes organic materials dissolved into liquid, best for low-cost high-output manufacturing. SolarWindow™ systems can undergo installation on the readily-available sizeable window glass surfaces on tall towers and skyscrapers.

SolarWindow™ can be applied to the sides of tall towers, generating electricity using natural, shaded, and artificial light. SolarWindow™ coatings generate electricity on see-through glass and flexible plastics with colored tints popular to skyscraper glass.

The Company’s SolarWindow™ technology has been independently validated to generate 50-times the power of a conventional rooftop solar system. Furthermore, it attains a one-year payback when modeled on a 50-story building.

SolarWindow™ products are undergoing development to be installed on all four sides of a skyscraper. This turns the whole building into a power generator. The Company’s latest products will be engineered as transparent, tinted, flexible veneers, which installers can apply directly over top of existing windows on tall towers and skyscrapers. This expanded product line extends its market reach beyond new and replacement installations, to include windows now installed on the estimated five million commercial buildings built in the U.S. alone.

SolarWindow Technologies entered Phase III of its Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL).

The chief development objective of the Agreement is the commercialization of SolarWindow™ products. In addition, SolarWindow™ is expanding product development to include applying its electricity-generating coatings onto flexible glass – as thin as a business card (only 0.1-millimeter-thick), which is flexible enough to be bent without breaking or cracking.

In late August of this year, SolarWindow Technologies announced that it entered into an agreement for the fabrication of SolarWindow™ products with suburban Los Angeles, California-based Triview Glass Industries, LLC. Triview Glass is SolarWindow Technologies’ select regional fabricator in North America. Triview will work to manufacture specific SolarWindow™ electricity-generating glass products at commercial scale through integrating SolarWindow™ technologies into its fabricating processes.

SolarWindow Technologies, Inc. (WNDW), closed Monday's trading session at $4.45, up 1.60%, on 52,527 volume with 118 trades. The average volume for the last 60 days is 128,444 and the stock's 52-week low/high is $2.50/$5.49.


The QualityStocks
Company Corner


Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.051, up 10.87%, on 763,611 volume with 76 trades. The stock’s average daily volume over the past 60 days is 363,673, and its 52-week low/high is $0.0161/$0.20.

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions (REFG) is “One to Watch”

Medical Cannabis Payment Solutions (REFG) to Purchase Industry Leading Cryptocurrency, Launch Joint Venture Aimed at Alternative Payment Solution for the Cannabis Industry

Medical Cannabis Payment Solutions Announces First Payment Processing Customer

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.495, up 4.21%, on 81,978 volume with 41 trades. The stock’s average daily volume over the past 60 days is 108,295 and its 52-week low/high is $0.40/$2.75.

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) reported a 76% year-over-year jump in operating sales in fiscal 2017. The company’s Investor Relations division boasted as the largest generator of corporate three-month revenues, contributing 62% of CIIX’s total sales for the period. An article discussing this reads: “ChineseInvestors.com, Inc. (OTCQB: CIIX) is driving revenue growth from its Investor Relations Division, realizing a 186% jump in sales for 1QFY2018. The first quarter revenue in FY2018 in this segment was $258,366 compared to sales of $90,312 in the first quarter of FY2017. To generate growth in FY2018, CIIX developed new products, such as multi-media and road show presentations for both brand- and company reputation- building, its 10K SEC filing reports (http://nnw.fm/Nx2M8). In FY 2017, sales of Investor Relations had been second to those of Subscriptions.”

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

NetworkNewsBreaks – ChineseInvestors.com, Inc.’s (CIIX) Investor Relations Division Generates Substantial Revenues

ChineseInvestors.com, Inc. Announces Board of Directors Appointments

ChineseInvestors.com, Inc. (CIIX) Launches New Daily Video Broadcast “Bitcoin Multimillionaire” By Teaming With Wall Street Multimedia, Inc.

LottoGopher Holdings Inc. (OTCQB:LTTGF) (CSE:LOTO) (FRA:2LG)

The QualityStocks Daily Newsletter would like to spotlight LottoGopher Holdings Inc. (LTTGF). Today, LottoGopher Holdings Inc. closed trading at $0.17, up 3.47%, on 161,153 volume with 75 trades. The stock’s average daily volume over the past 60 days is 156,299 and its 52-week low/high is $0.15/$0.50.

LottoGopher Holdings Inc. (CSE: LOTO) (OTCQB: LTTGF) (FSE: 2LG) was pleased to announce today the addition of Jeff Koyen as an Independent Advisor. Mr. Koyen will guide the company in developing and launching applicable blockchain technologies as it relates to online lottery, including the verification of ticket ownership on a public ledger. Mr. Koyen, a cryptocurrency and blockchain investor, trader and enthusiast, is also an award-winning journalist and media strategist. Previously, he held editorships with New York Press, Forbes Traveler, Travel and Leisure, Dow Jones Mansion Global, Vocativ, and Digiday. He was recently appointed Strategic Advisor for 360 Blockchain.

LottoGopher Holdings Inc. (LTTGF) is a new lottery messenger service that provides its subscribers with the security of ordering and managing the legal purchase of state lottery tickets online using debit and credit cards. LottoGopher makes it simple for users to keep track of tickets and winnings. Members have exclusive access to strategies, alerts, lottery news and can play alone with a single ticket or join online public or private groups to pool winnings.

LottoGopher is transforming the lottery buying experience, which has historically meant taking the time and spending the gas money to drive to a retail location, then stand in line to buy via cash only and redeem tickets. LottoGopher's uniquely online messenger service streamlines the experience of taking a shot at the lottery and makes it much more convenient and access to electronic payment, otherwise not permitted in CA. While only California residents at this time can play Mega Millions, SuperLotto Plus and Powerball through LottoGopher.com, expansion plans are in the works to allow internet-savvy residents in 22 other states with legal lotteries to have the same advantages of purchasing tickets online.

LottoGopher also enjoys a strategic business relationship with Lottoland, ranked in the Financial Times' FT1000 Report as one of Britain's Top 30 fastest growing companies and as the second ranked gaming company in Europe. Since launching in 2013, Lottoland has rapidly become a world leader in the online lottery sector with nearly $357 million (U.S. dollars) in annual sales.

LottoGopher's currently integrated support systems include a mobile friendly platform; automated email follow-up system to capture, score and remarket to email address leads; social media listening and outreach; utilization of Google Analytics tools; one-time promotional offers across multiple platforms; main and backup credit card processing accounts; and focus on customer service.

Customers of LottoGopher pay a subscription fee to use the service, much like Netflix, Amazon Prime or Dollar Shave Club. After selecting their subscription plan, users pay the same price per ticket as if purchasing from a retail, brick-and-mortar location. LottoGopher's team then secures the selected tickets from a lottery retailer partner. User account balances are updated after a drawing, which makes it impossible for a member to "lose" a winning ticket.

The company's target market includes the 80 million U.S. consumers already buying lottery tickets who typically purchase products online. Offering a far more convenient way to play the lottery via an intuitive platform, LottoGopher is well positioned to disrupt this multi-billion dollar industry. Disclaimer

LottoGopher Holdings Inc. Blog

LottoGopher Holdings Inc. News:

LottoGopher Holdings Inc. Plans to Develop and Launch 'Lottery Blockchain'

NetworkNewsWire Announces Publication Harnessing the Power of Celebrity Endorsements

NetworkNewsWire Releases Exclusive Audio Interview with LottoGopher Holdings Inc.

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0215, up 10.26%, on 4,551,327 volume with 205 trades. The stock’s average daily volume over the past 60 days is 3,289,330, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) was pleased today to announce that its majority owned subsidiary, MoneyTrac Technology, Inc., in addition to its newly acquired marketing and publishing entity, PotSaver, plans to expand the brand’s reach by attending the MJ Business Conference and Expo from November 14 through the 17th in Las Vegas, Nevada.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout’s MoneyTrac Technology, Inc. Heads to MJ Business Conference in Las Vegas

Global Payout’s MoneyTrac Technology, Inc. and Strategic Partner Pegasus Fintech, Inc. Make Strides with Development of Cryptocurrency Token for Cannabis Industry and Move Closer to Launch of ICO

Global Payout, Inc. is in the Process of Exploring New Partnerships to Take Advantage of the Fast-Growing Logistics Industry

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.6169, up 13.92%, on 2,439,663 volume with 1,133 trades. The stock’s average daily volume over the past 60 days is 589,427, and its 52-week low/high is $0.09/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication that Highlights Big Pharma's Increasing Interest in Cannabis Biotech Companies

NetworkNewsWire Announces Publication Highlighting Big Pharma's Appetite for M&A Possibilities in Cannabis

Biotech M&A Momentum Attractive for Cannabinoid R&D Space

92 Resources Corp. (TSX.V:NTY) (OTCQB:RGDCF) (FSE:R9G2)

The QualityStocks Daily Newsletter would like to spotlight 92 Resources Corp. (RGDCF). Today, 92 Resources Corp. closed trading at $0.093, up 11.24%, on 164,855 volume with 15 trades. The stock’s average daily volume over the past 60 days is 26,429 and its 52-week low/high is $0.071/$0.109.

92 Resources Corp. (TSX.V: NTY) (OTCQB: RGDCF) is a modern energy solutions company focused on acquiring and advancing strategic and prospective energy-related projects in Canada. Its three principal assets include the Hidden Lake Lithium Property in the Northwest Territories, the Pontax Lithium Property in Quebec, and the Golden Frac Sand Property in British Columbia.

Preliminary mineralogy work on samples taken of the Hidden Lake pegmatites indicate spodumene – the world's richest source of lithium – is of a high quality and near the maximum theoretical limit. Scoping testwork saw an overall lithium extraction of 97 percent from the concentrate produced from these pegmatites, which means standard lithium extraction techniques can be applied, making the extraction of lithium easier and more cost effective.

92 Resources is focused on developing the lithium-rich resources located within its properties through open-pit mining and relatively straight-forward mineral processing procedures. Surface exploration programs that include prospecting, mapping and sampling of known spodumene-bearing pegmatites on the Hidden Lake property suggests the existence of one massive, interconnected body of pegmatite below the surface. Recent acquisitions of prospective hard-rock lithium properties in Quebec add to the company's impressive and growing asset portfolio.

Recent acquisitions of prospective hard-rock lithium properties in Quebec add to the company's impressive and growing asset portfolio. The properties, known as Corvette, Eastmain and Lac Du Beryl, consist of a combined 115 mineral claims totaling approximately 14,710 acres with confirmed pegmatite outcrops visible at each location. Some sampling has been completed at the Corvette property and shows spodumene crystals present, making this location a high priority for follow up work. Analytical results are pending on samples taken from known pegmatite outcrops visible at each property.

Lithium is a strategic, green metal used in batteries, electronics, electric vehicles, ceramics, alloys, lubricants and pharmaceuticals. The world market for electric vehicles, with China as its biggest customer, is exponentially growing as the demand for clean, renewable energy sources increases. A recent report by Grand View Research, Inc. places the lithium-ion battery market worldwide at $93 billion by 2025, with a compound annual growth rate of 17%.

92 Resources is led by an experienced management team and advisors with decades of expertise in market strategies, corporate development, mineral exploration and energy development. With an excellent team of professionals and promising mining projects, the company is well positioned to capitalize on the ever-rising demand for lithium. Disclaimer

92 Resources Corp. Blog

92 Resources Corp. News:

NetworkNewsWire Announces Publication Discussing the Impact of Lithium Demand on Several Public Companies

Lithium, Fuelling the New Millennium

92 Resources Corp. Acquires Three New Properties in Quebec

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.0378, up 2.16%, on 56,000 volume with 5 trades. The stock’s average daily volume over the past 60 days is 19,602, and its 52-week low/high is $0.007/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Trader Power News
(CHKE) +52.63%


(LTUM) +45.57%


(ROKU) +28.45%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251